$7,70
▼ $-0,32
(-3,99%)
Vol. 4.7M
8
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$1.1B
P/E
3,2
ROE
283,1%
Margine
32,1%
D/E
607,28
Beta
2,66
52W
$5–$12
Consenso Wall Street
15 analisti · Apr 20264
Acquisto forte
6
Compra
2
Mantieni
2
Vendi
1
Vendita forte
66,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
GLUE
Monte Rosa Therapeutics Inc
P/E 48,7
$1.0B
BCAX
Bicara Therapeutics Inc
$922.0M
OLMA
Olema Pharmaceuticals Inc
$2.0B
ZBIO
Zenas Biopharma Inc
$2.3B
TSHA
Taysha Gene Therapies Inc
$1.5B
CRVS
Corvus Pharmaceuticals Inc
$575.1M
SVRA
Savara Inc
$1.2B
AVBP
ArriVent BioPharma Inc
$830.6M
GERN
Geron Corp
$842.6M
KALV
Kalvista Pharmaceuticals Inc
$816.3M
Utili
Tasso di battuta: 75,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-0,24
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,24 | — | — |
| Dic 2025 | $-0,50 | $0,11 | +$0,61 |
| Set 2025 | $-1,21 | $-1,25 | $-0,04 |
| Giu 2025 | $-0,09 | $0,62 | +$0,71 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 283.1% | 283.1% | 283.1% | 283.1% | 283.1% | 283.1% |
| P/E (TTM) | 2.41 | 3.46 | 3.70 | 3.23 | 3.14 | 3.20 |
| Net Margin | 44.5% | 39.2% | 39.2% | 39.2% | 32.1% | 32.1% |
| Gross Margin | 93.6% | 88.3% | 88.3% | 88.3% | 91.8% | 91.8% |
| D/E Ratio | 607.28 | 607.28 | 607.28 | 607.28 | 607.28 | 607.28 |
| Current Ratio | 2.36 | 2.36 | 2.36 | 2.36 | 2.27 | 2.27 |
Rapporti chiave
ROA (TTM)
25,5%
P/S (TTM)
1,03
P/B
11,3
EPS (TTM)
$1,77
CF/Share
$-5,39
Crescita ricavi 3A
-15,9%
52W High
$11,55
52W Low
$5,01
$5,01
Intervallo 52 settimane
$11,55
Як NVAX виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка NVAX vs аналоги Biotechnology
P/E
3,2
▼
83%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
1,0
▼
92%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
11,3
▲
360%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість NVAX vs аналоги Biotechnology
ROE
283,1%
▲
521%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
32,1%
▲
111%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
91,8%
▲
17%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
25,5%
▲
155%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя NVAX vs аналоги Biotechnology
D/E ratio
607,3
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
2,3
▼
49%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
2,7
▲
174%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів NVAX
NVAX
Mediana peer
Industria
NVAX прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio